Zentalis Pharmaceuticals ZNTL 深 滬
交易中 09-19 12:12:14 美东时间
4.39
+0.230
+5.53%
華盛通- 最 高4.46
- 今 開4.32
- 成交量 95.62万股
- 最 低 4.21
- 昨 收 4.16
- 總市值 3.11亿
- 52周最高 21.34
- 市盈率 靜 --
- 換手率 1.35%
- 52周最低 2.83
- 委 比 81.87%
- 總股本 7076.58万
- 歷史最高 87.19
- 量 比 0.23
- 振 幅 6.01%
- 歷史最低 2.83
- 每 手 1
- 風險率 5.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Oppenheimer Reiterates Outperform on Zentalis Pharma, Maintains $20 Price Target
Oppenheimer analyst Matthew Biegler reiterates Zentalis Pharma (NASDAQ:ZNTL) with a Outperform and maintains $20 price target.
09-17 01:52
Walgreens Agrees To $106.8M Settlement Over Alleged False Billing Claims
Walgreens agrees to pay $106.8 million to settle claims of false billing to federal health care programs. The settlement addresses fraudulent activities between 2009 and 2020 and includes significant whistleblower rewards.
09-16 23:45
Market-Moving News for September 16th
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrolizumab For Patients With Metastatic Melanoma Who Were Refractory To Or Had Relapsed On
09-16 20:08
Zentalis Pharmaceuticals Advances with FDA Approval and Upcoming Data
Zentalis Pharmaceuticals ( ($ZNTL) ) just unveiled an announcement. Zentalis Ph...
09-16 19:29
快讯 | zentalis pharmaceuticals宣布FDA已解除对Azenosertib研究的部分临床暂停
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azen...
09-16 19:00
快讯 | Zentalis Pharmaceuticals Inc - 按计划符合2024年数据指引
Zentalis Pharmaceuticals Inc - on Track to Meet 2024 Data Guidance
09-16 19:00
快讯 | zentalis pharmaceuticals宣布按照纳斯达克列示规则5635（C）（4）颁发诱因津贴。
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule ...
09-04 04:41
快讯 | Zentalis Pharmaceuticals Inc: Stifel将目标价从$10降至$9
Zentalis Pharmaceuticals Inc : Stifel Cuts Target Price to $9 From $10
08-12 19:26
快讯 | Zentalis Pharmaceuticals公司：Wedbush将其评级由表现不佳升至中立
Zentalis Pharmaceuticals Inc : Wedbush Raises to Neutral From Underperform
08-12 18:00
Zentalis Pharmaceuticals GAAP EPS of -$1.24
Zentalis Pharmaceuticals press release (NASDAQ:ZNTL): Q2 GAAP EPS of -$1.24. Cash, Cash Equivalents and Marketable Securities Position: As of June 30, 2024, Zentalis had cash, cash equivalents and mar...
08-09 22:09
